Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

NCT05879484 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Study was never opened for enrollment as the CRADA was never executed

Conditions

Sinonasal Cancer
Squamous Non-small Cell Lung Cancer
Lung Cancer
Head and Neck Squamous Cell Carcinoma
Head and Neck Carcnimona
Head and Neck Cancer

Interventions

DRUG: pembrolizumab
DRUG: valemetostat

Sponsor

National Cancer Institute (NCI)